• Retractable Technologies posted an operating loss of USD 6.2 million for quarter ended March 31, 2026, widening from about USD 4.7 million a year earlier.
• Domestic revenue fell 20% as domestic unit sales dropped 11.5%, with domestic sales accounting for 82.9% of total revenue versus 89.6% a year earlier.
• International revenue climbed 42.4% on higher EasyPoint needle sales, while overall unit sales rose 3.6%.
• Operating expenses increased 14% primarily due to higher donation expense, while tariff expense totaled USD 11,600 and was down versus prior periods.
• Management expects international sales to increase in second half of 2026 following EU Medical Device Regulation certification, while a 16% workforce cut in April is expected to save about USD 2.2 million annually with USD 122,000 in one-time separation costs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Retractable Technologies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-062253), on May 15, 2026, and is solely responsible for the information contained therein.